Jubilant Therapeutics Inc Overview
Pro stress-test →Jubilant Therapeutics is a patient-focused biopharmaceutical company advancing potent and selective small molecule modulators to address specific unmet medical needs in oncology and autoimmune diseases. The company leverages the proven and synergistic capabilities of Jubilant Pharmova's value chain and shared services, guided by renowned scientific advisory board members, and is headquartered in the U.S.
Strategic Profile
Pro stress-test →Jubilant Therapeutics has a dual small-molecule inhibitor targeting lysine demethylase (LSD1) and HDAC6 that has demonstrated superior anti-proliferative activity and biomarker modulation in preclinical models and is undergoing IND-enabling studies. The company is building a pipeline across multiple therapeutic mechanisms in oncology and inflammation-driven indications.
Competitive Landscape
Pro stress-test →Jubilant Therapeutics competes in the oncology and autoimmune therapeutics space against clinical-stage biotech companies developing small-molecule inhibitors and immunomodulators. Direct competitors include companies pursuing similar target modalities (LSD1/HDAC6, PAD4, PRMT5) and checkpoint modulation approaches, alongside established pharma players with oncology pipelines.
Industry Context
Jubilant Therapeutics Inc operates in Oncology and autoimmune small-molecule therapeutics.
Key facts
Founded: 2007 · Headquarters: San Diego, US · Employees: N/A · Revenue: N/A · Market cap: N/A